Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    11821454 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma
Condition: Untreated CD20-Positive Large B-Cell Lymphoma
Interventions: Drug: Rituximab + ACVBP regimen plus Pegfilgrastim;   Procedure: Autologous stem cell transplant
2 Completed Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy
Conditions: Hematological Neoplasms;   Tumors
Interventions: Drug: Filgrastim;   Drug: Pegfilgrastim
3 Recruiting Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation
Condition: Non Hodgkin Lymphoma
Interventions: Drug: Pegfilgrastim;   Drug: Filgrastim

Indicates status has not been verified in more than two years